A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) ...

Molecule sends 13 of the 17 most common forms of this cancer-related protein to the cell’s garbage-disposal system ...

KRAS-G12D and KRAS-G12V being the most common alleles, and may provide doctors with valuable information about patient prognosis. “We found that there are significant differences among these mutations ...

Jazz’s move into the KRAS category comes shortly after AstraZeneca licensed a KRAS G12D inhibitor from Chinese biotech Usynova for $24 million upfront in a deal that also includes up to $395 ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

这款名为ACBI3的PROTAC分子基于勃林格殷格翰公司已经开发的一款泛KRAS抑制剂BI-2865。它在临床前研究中已经表现出抑制多种KRAS突变体和野生型KRAS蛋白的活性。这款泛KRAS抑制剂的临床前研究已于去年发表在《自然》杂志上。

Silexion Therapeutics' stock surged after the company revealed preclinical findings for SIL-204, its siRNA candidate.

Medigene continually extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains 29 different patent families ...

也就是说，Mirati此前要求法院确认相关专利权/专利申请权归Mirati与亚雷公司所有，并要求公司、美国益方及代星共同赔偿米拉蒂公司经济损失及合理费用合计人民币9900万元的诉求被驳回。

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...